Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2002 1
2006 1
2007 1
2009 1
2010 1
2011 4
2012 3
2013 4
2015 4
2016 3
2017 3
2018 3
2019 5
2020 5
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for C. maraveyas
Search for C. Maraveas instead (1 results)
Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials.
Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, Catalano M, Spyropoulos AC, Schulman S, Douketis J, Falanga A, Maraveyas A, Olinic DM, Belch J, Gerotziafas G, Syrigos K, Kollias A; COVID-19 Thrombosis Collaborative Group, Endorsed by VAS-European Independent Foundation in Angiology/Vascular Medicine, UEMS Division of Angiology/Vascular Medicine/and ESVM-European Society of Vascular Medicine and Supported by the Balkan Working Group. Kyriakoulis KG, et al. J Clin Med. 2022 Oct 11;11(20):5997. doi: 10.3390/jcm11205997. J Clin Med. 2022. PMID: 36294316 Free PMC article. Review.
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol.
Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Garcia D, Lyman G, Noble S, Macbeth F, Griffiths G, DiNisio M, Iorio A, Beyene J, Mbuagbaw L, Neumann I, Van Es N, Brouwers M, Brozek J, Guyatt G, Levine M, Moll S, Santesso N, Streiff M, Baldeh T, Florez I, Gurunlu Alma O, Solh Z, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Buller H, Evans J, McBane R, Bleker S, Pelzer U, Akl EA; IPDMA heparin use in cancer patients research group. Schünemann HJ, et al. BMJ Open. 2016 Apr 29;6(4):e010569. doi: 10.1136/bmjopen-2015-010569. BMJ Open. 2016. PMID: 27130164 Free PMC article. Review.
Towards optimal use of antithrombotic therapy of people with cancer at the end of life: A research protocol for the development and implementation of the SERENITY shared decision support tool.
Goedegebuur J, Abbel D, Accassat S, Achterberg WP, Akbari A, Arfuch VM, Baddeley E, Bax JJ, Becker D, Bergmeijer B, Bertoletti L, Blom JW, Calvetti A, Cannegieter SC, Castro L, Chavannes NH, Coma-Auli N, Couffignal C, Edwards A, Edwards M, Enggaard H, Font C, Gava A, Geersing GJ, Geijteman ECT, Greenley S, Gregory C, Gussekloo J, Hoffmann I, Højen AA, van den Hout WB, Huisman MV, Jacobsen S, Jagosh J, Johnson MJ, Jørgensen L, Juffermans CCM, Kempers EK, Konstantinides S, Kroder AF, Kruip MJHA, Lafaie L, Langendoen JW, Larsen TB, Lifford K, van der Linden YM, Mahé I, Maiorana L, Maraveyas A, Martens ESL, Mayeur D, van Mens TE, Mohr K, Mooijaart SP, Murtagh FEM, Nelson A, Nielsen PB, Ording AG, Ørskov M, Pearson M, Poenou G, Portielje JEA, Raczkiewicz D, Rasmussen K, Trinks-Roerdink E, Schippers I, Seddon K, Sexton K, Sivell S, Skjøth F, Søgaard M, Szmit S, Trompet S, Vassal P, Visser C, van Vliet LM, Wilson E, Klok FA, Noble SIR. Goedegebuur J, et al. Thromb Res. 2023 Aug;228:54-60. doi: 10.1016/j.thromres.2023.05.008. Epub 2023 May 13. Thromb Res. 2023. PMID: 37276718 Free article.
Investigation of the Filamin A-Dependent Mechanisms of Tissue Factor Incorporation into Microvesicles.
Collier MEW, Ettelaie C, Goult BT, Maraveyas A, Goodall AH. Collier MEW, et al. Thromb Haemost. 2017 Nov;117(11):2034-2044. doi: 10.1160/TH17-01-0009. Epub 2017 Nov 30. Thromb Haemost. 2017. PMID: 29044292
Here, we examined the contribution of the individual phosphorylation of these serine residues to the interaction between filamin A and TF, and further examined how filamin A regulates the incorporation of TF into MVs. In vitro binding assays using recombinant filamin A C-t …
Here, we examined the contribution of the individual phosphorylation of these serine residues to the interaction between filamin A and TF, a …
Reduction of streptavidin RYDS-mediated renal adhesion by site-directed mutagenesis.
Murray S, Maraveyas A, Dougan T, Chu AC. Murray S, et al. Biochim Biophys Acta. 2002 Mar 15;1570(2):81-8. doi: 10.1016/s0304-4165(02)00157-5. Biochim Biophys Acta. 2002. PMID: 11985891
RYDS-c-Streptavidin and RYES-c-Streptavidin were expressed in E. coli and purified on a 2-imminobiotin matrix. ...RYDS-c-Streptavidin-mediated kidney cell attachment was inhibited by competition with c-Streptavidin, RYDS-c-Streptavidin and RGDS- …
RYDS-c-Streptavidin and RYES-c-Streptavidin were expressed in E. coli and purified on a 2-imminobiotin matrix. ...RYDS-c …
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Seymour MT, et al. Lancet. 2007 Jul 14;370(9582):143-152. doi: 10.1016/S0140-6736(07)61087-3. Lancet. 2007. PMID: 17630037 Clinical Trial.
Strategy B was fluorouracil until failure, then combination chemotherapy. Strategy C was combination chemotherapy from the outset. Within strategies B and C, patients were randomly assigned to receive, as the combination regimen, fluorouracil plus irinotecan (groups …
Strategy B was fluorouracil until failure, then combination chemotherapy. Strategy C was combination chemotherapy from the outset. Wi …
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
Mahé I, Agnelli G, Ay C, Bamias A, Becattini C, Carrier M, Chapelle C, Cohen AT, Girard P, Huisman MV, Klok FA, López-Núñez JJ, Maraveyas A, Mayeur D, Mir O, Monreal M, Righini M, Samama CM, Syrigos K, Szmit S, Torbicki A, Verhamme P, Vicaut E, Wang TF, Meyer G, Laporte S. Mahé I, et al. Thromb Haemost. 2022 Apr;122(4):646-656. doi: 10.1055/a-1647-9896. Epub 2021 Nov 5. Thromb Haemost. 2022. PMID: 34535037 Free PMC article. Clinical Trial.
39 results